Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 23667255
Zhang Y, et al. (2013) The Nuclear Import of Oncoprotein Hepatitis B X-interacting Protein Depends on Interacting with c-Fos and Phosphorylation of Both Proteins in Breast Cancer Cells. J Biol Chem 288, 18961-74 23667255
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T232-p - Fos (human)
Modsite: GGLPEVAtPESEEAF SwissProt Entrez-Gene
Orthologous residues
Fos (human): T232‑p, Fos (mouse): T232‑p, Fos (rat): T232‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease
siRNA decrease siRNA for ERK1 decreases phosphorylation
HBXIP (human) increase siRNA inhibits
PD98059 HBXIP (human) inhibit treatment-induced increase

T325-p - Fos (human)
Modsite: TELEPLCtPVVTCtP SwissProt Entrez-Gene
Orthologous residues
Fos (human): T325‑p, Fos (mouse): T325‑p, Fos (rat): T325‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease
siRNA decrease siRNA for ERK1 decreases phosphorylation
HBXIP (human) increase siRNA inhibits
PD98059 HBXIP (human) inhibit treatment-induced increase

T331-p - Fos (human)
Modsite: CtPVVTCtPSCTAYT SwissProt Entrez-Gene
Orthologous residues
Fos (human): T331‑p, Fos (mouse): T331‑p, Fos (rat): T331‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease
siRNA decrease siRNA for ERK1 decreases phosphorylation
HBXIP (human) increase siRNA inhibits
PD98059 HBXIP (human) inhibit treatment-induced increase

S374-p - Fos (human)
Modsite: PSSDSLSsPtLLAL_ SwissProt Entrez-Gene
Orthologous residues
Fos (human): S374‑p, Fos (mouse): S374‑p, Fos (rat): S374‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease
siRNA decrease siRNA for ERK1 decreases phosphorylation
HBXIP (human) increase siRNA inhibits
PD98059 HBXIP (human) inhibit treatment-induced increase

S26-p - HBXIP (human)
Modsite: VGVLCTDsQGLNLGC SwissProt Entrez-Gene
Orthologous residues
HBXIP (human): S26‑p, HBXIP (mouse): S26‑p, HBXIP iso2 (mouse): S80‑p, HBXIP (rat): S91‑p
Characterization
Methods used to characterize site in vivo [32P] ATP in vitro, immunoassay, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ATM (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ATM (human) co-immunoprecipitation, modification site within consensus motif, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease siRNA fo ATM decreases phosphorylation
ERK1 (human) no change compared to control siRNA
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation, phosphorylation
Effect of modification (process):  carcinogenesis, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Fos (human) Induces co-immunoprecipitation, pull-down assay, microscopy-colocalization
Comments:  phosphorylation of c-Fos